Efavirenz Synthesis via Diphosgene One-Step Process
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for producing Efavirenz, a non-nucleoside reverse transcriptase inhibitor, are inefficient due to lengthy reaction times and complex work-ups, particularly when using chloroformate derivatives, and lack a one-step process with trichloromethylchloroformate as a reactant.
Innovation Solution
A one-step process involving the reaction of intermediate (2S)-2-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol with diphosgene in neutral or slightly basic conditions, allowing for the direct synthesis of Efavirenz with high yield and purity without the need for isolating intermediates, using a biphasic medium and a weak base to manage reaction pH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional chloroformate derivatives are used in basic conditions, then Efavirenz can be obtained with acceptable impurity profile, but the reaction time becomes lengthy (1 to 6 hours) and the work-up procedure becomes complicated requiring isolation of intermediate
Solution Approach 1:
The patent changes the reaction conditions by using diphosgene instead of conventional chloroformate derivatives, and employs weak base catalysts (carbonates, bicarbonates, or hydroxides) at controlled amounts (0.01-2.0 equivalents) to achieve faster reaction (0.5-4 hours) while maintaining acceptable impurity profiles. The use of specific solvents (dichloromethane, chloroform, or their mixtures) also optimizes the reaction parameters.
Solution Approach 2:
The patent introduces weak base catalysts (such as sodium carbonate, potassium bicarbonate, or lithium hydroxide) as intermediaries to facilitate the reaction between diphosgene and the amino alcohol intermediate. These weak bases mediate the reaction by neutralizing the strong acidity of diphosgene while enabling carbamate formation, thus improving reaction efficiency without requiring strong base conditions that would complicate the work-up.
2Ease of manufacture
If conventional processes are used, then Efavirenz can be produced, but the work-up procedure becomes complicated requiring separation and concentration before cyclization
Solution Approach 1:
The patent combines the carbamate formation and cyclization steps into a single one-pot reaction sequence. The amino alcohol intermediate is treated with diphosgene in the presence of weak base catalyst in a suitable solvent, and the cyclization occurs in situ without isolating the carbamate intermediate. This merging of steps eliminates the need for separate isolation and concentration operations, simplifying the work-up procedure and improving overall process efficiency.
3Productivity
If diphosgene is used as reactant, then one-step process with short reaction time and high yield is achieved, but the reaction conditions must be precisely controlled to manage the strong acidity of diphosgene
Solution Approach 1:
The patent carefully controls reaction parameters when using diphosgene: employing weak base catalysts (carbonates, bicarbonates, or hydroxides) in specific amounts (0.01-2.0 equivalents relative to diphosgene), maintaining reaction temperature between -20°C to 50°C, and using appropriate solvents (dichloromethane, chloroform, or their mixtures). These parameter controls manage diphosgene's strong acidity while enabling the one-step process to proceed efficiently with high yield.
Solution Approach 2:
Weak base catalysts serve as intermediaries that neutralize the strong acidity of diphosgene, enabling safe and efficient reaction conditions. The weak bases (such as sodium carbonate, potassium bicarbonate, or lithium hydroxide) react with the HCl generated during carbamate formation, preventing side reactions and facilitating the one-step transformation without requiring complex condition control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method significantly reduces reaction time to less than an hour, enhances the purity profile of Efavirenz to over 99.8%, and minimizes residual impurities, improving the overall efficiency and yield compared to previous methods.
Implementation Method 1
reacting intermediate (II) free base to give Efavirenz
Implementation Method 2
biphasic medium comprised of an organic solvent and water
Implementation Method 3
weak base in an amount sufficient to neutralise the reaction mixture... capture hydrogen chloride that is delivered by the reacting diphosgene
Data Source
AI summary
The present invention is directed to a process for the preparation of Efavirenz, (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one, of formula (I) comprising reacting the intermediate of formula (II) [0045] as a free base or a salt thereof, with diphosgene (TCMCF, trichlormethylchloroformate) Cl3CO-COCl in an organic solvent or in a biphasic medium comprised of an organic solvent and water, preferably but not mandatorily in the presence of a weak base in an amount sufficient to neutralise the reaction mixture or in an up to 30% molar excess of such amount.